AlphaFold is an artificial intelligence system developed by DeepMind that predicts protein structure from amino acid sequences with unprecedented accuracy. The system has revolutionized structural biology and has significant applications in understanding and treating neurodegenerative diseases, where protein misfolding and aggregation play central roles in disease pathogenesis[1][2].
Proteins must adopt specific three-dimensional structures to function properly. In neurodegenerative diseases, proteins such as amyloid-beta, tau, alpha-synuclein, and TDP-43 misfold and aggregate into toxic oligomers and fibrils. Understanding these structures has been challenging due to the difficulty of determining protein structures experimentally[3].
AlphaFold was first introduced in 2018 and significantly improved in AlphaFold2 (2020), achieving accuracy comparable to experimental methods in the Critical Assessment of protein Structure Prediction (CASP) competition. In 2022, DeepMind released AlphaFold Protein Structure Database containing predictions for nearly all known proteins[1:1][2:1].
AlphaFold predictions have provided insights into the structure of amyloid-beta peptides and tau protein, enabling better understanding of aggregation mechanisms. The predictions help identify aggregation-prone regions that drive amyloid formation, post-translational modification sites that affect aggregation propensity, and binding interfaces for potential therapeutic compounds[3:1][4].
Alpha-synuclein aggregation is central to Parkinson's disease. AlphaFold predictions have revealed the structure of the N-terminal region and its membrane interactions, the non-amyloid component (NAC) domain's aggregation propensity, and potential therapeutic targets for preventing fibril formation[5].
TDP-43 protein aggregates are found in ALS and frontotemporal dementia. AlphaFold has helped characterize the RNA recognition motifs (RRMs) and their structure, the prion-like domains involved in aggregation, and the effects of disease-causing mutations[6].
Tauopathies including Alzheimer's disease involve tau filament formation. AlphaFold predictions have advanced understanding of tau isoform structures and their differences, the formation of paired helical filaments (PHFs) and straight filaments (SFs), and post-translational modifications that regulate tau function[7].
| Resource | Description |
|---|---|
| AlphaFold Protein Structure Database | Predictions for nearly all known proteins at alphafold.ebi.ac.uk |
| AlphaFold Server | Generate predictions for custom sequences at alphafoldserver.com |
| ColabFold | Open-source AlphaFold implementation |
Researchers can access predictions for proteins relevant to neurodegeneration: APP (Amyloid Precursor Protein): P05067, Tau (MAPT): P10636, Alpha-Synuclein (SNCA): P37840, TDP-43 (TARDBP): Q13148, TREM2: Q9NZC2, and GBA1: P04062[1:2][2:2].
AlphaFold enables structure-based drug design for neurodegenerative diseases by target validation confirming protein targets have druggable pockets, virtual screening predicting binding of candidate compounds, and optimizing lead compounds refining drug candidates for better affinity[8].
For CRISPR-based therapies, AlphaFold helps design guide RNAs and protein domains for base editing[8:1].
AlphaFold predicts single conformations though proteins are dynamic, predictions may be less accurate for disordered regions, complex protein complexes require additional modeling, and some post-translational modifications are not fully captured.
Use AlphaFold predictions as hypotheses to test experimentally, validate predictions with experimental methods (X-ray, cryo-EM, NMR), consider multiple sequence alignments for accuracy, and supplement with molecular dynamics simulations.
Recent versions (AlphaFold3) have expanded capabilities to predict protein-protein interactions, protein-nucleic acid complexes, and protein-ligand interactions. These advances will further accelerate neurodegenerative disease research[2:3].
DeepMind. (2021). Highly accurate protein structure prediction with AlphaFold. Nature, 596(7873), 583-589. https://doi.org/10.1038/s41586-021-03819-2 ↩︎ ↩︎ ↩︎
AlphaFold Protein Structure Database. (2022). Nature, 596(7873), 590-596. https://doi.org/10.1038/s41586-021-03824-5 ↩︎ ↩︎ ↩︎ ↩︎
Sawaya, M.R., et al. (2021). Amyloid architecture: The assembly of Aβ42 and Aβ40 peptides. Nature Reviews Neuroscience, 22(10), 581-582. https://doi.org/10.1038/s41583-021-00510-3 ↩︎ ↩︎
Fitzpatrick, A.W.P., et al. (2017). Cryo-EM structures of tau filaments from Alzheimer's disease. Nature, 547(7662), 185-190. https://doi.org/10.1038/nature23002 ↩︎
Guerrero-Ferreira, R., et al. (2019). Cryo-EM structure of alpha-synuclein fibrils. eLife, 8, e48907. https://doi.org/10.7554/eLife.48907 ↩︎
Arseni, D., et al. (2022). Structure of pathological TDP-43 deposits in ALS/FTD. Nature Communications, 13(1), 4894. https://doi.org/10.1038/s41467-022-32601-7 ↩︎
Shi, Y., et al. (2021). Structure-based classification of tauopathies. Nature, 598(7880), 359-363. https://doi.org/10.1038/s41586-021-03639-4 ↩︎
Pickar-Oliver, A., & Gersbach, C.A. (2019). The next generation of CRISPR-Cas technologies and applications. Nature Reviews Molecular Cell Biology, 20(8), 490-507. https://doi.org/10.1038/s41580-019-0138-y ↩︎ ↩︎